Clinical Trial Update: FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FOLFOX with or without Ziv-Aflibercept in esophageal and gastric cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• FOLFOX
• Ziv-aflibercept (ziv-aflibercept)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-05-08